evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,808 questions · 8,953 findings · 827 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,891 · 21.1%GRADE not reported 380 · 4.2%Very low 2,100 · 23.5%Low 2,449 · 27.4%Moderate 1,684 · 18.8%High 449 · 5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Aspirin vs vitamin K antagonist (VKA)

All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with vitamin K antagonist (VKA) (very low certainty).

2 findings from 1 review

Aspirin vs low molecular weight heparin

All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Aspirin vs low molecular weight heparin

Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes symptomatic deep vein thrombosis compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Aspirin vs low molecular weight heparin

Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes pulmonary embolism compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Aspirin vs low molecular weight heparin

Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes major bleeding compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Aspirin vs vitamin K antagonist (VKA)

Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes symptomatic deep vein thrombosis compared with vitamin K antagonist (VKA) (very low certainty).

2 findings from 1 review

Vitamin K antagonists vs low molecular weight heparin

All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether vitamin K antagonist (VKA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Vitamin K antagonists vs low molecular weight heparin

Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether vitamin K antagonist (VKA) changes symptomatic deep vein thrombosis compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Vitamin K antagonists vs low molecular weight heparin

Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether vitamin K antagonist (VKA) changes pulmonary embolism compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Vitamin K antagonists vs low molecular weight heparin

Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents

The review found no eligible studies for this question.

2 findings from 1 review

Vitamin K antagonists vs low molecular weight heparin

Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether vitamin K antagonist (VKA) changes minor bleeding compared with low molecular weight heparin (LMWH) (very low certainty).

1 finding from 1 review

Aspirin vs vitamin K antagonist (VKA)

Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes pulmonary embolism compared with vitamin K antagonist (VKA) (very low certainty).

2 findings from 1 review